Drug Trial Radar · NCT05597163
Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Jan 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
588
Planned (sponsor's estimate)
Start
Jan 15, 2023
Primary completion
Nov 1, 2024
Study completion Nov 1, 2025
Sponsor
- Lead sponsor
- Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Peking University People's Hospital; Shandong University of Traditional Chinese Medicine
- First posted
- Oct 27, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the efficacy and safety of three low-concentration atropine sulfate eye drops (0.01%, 0.025% and 0.05%) in controlling the progression of myopia in Chinese children and adolescents through a two-year clinical trial.
Conditions
- Myopia, Progressive
Interventions
low concentration atropine (0.01%)Drug
0.01% atropine eye drop
low concentration atropine (0.025%)Drug
0.025% atropine eye drop
low concentration atropine (0.05%)Drug
0.05% atropine eye drop
PlaceboDrug
Placebo eye drop
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of SE changes over -0.75DTime frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.